SAGAsafe® EGFR T790M Mutation Detection Assay

Benefit from the highest sensitivity monitoring

Read more

Life Changing Technology

Ultrasensitive cancer diagnostics & monitoring

Read more

The Liquid Biopsy Advantage

Oncologists worldwide are experiencing a revolution

Read more

Ensures the Best Decisions

Vastly improved genomic sensitivity

Read more

Boosts Clinical Trials

Gain new insights to speed new drug approvals

Read more

100x Increased Sensitivity.
Made Possible by a Simple Blood Test.

Watch the video

For Laboratories

A vital upgrade for Core labs & cancer patients

Read More

For Biopharma

Clinical Trials: a gamechanger for Biopharma

Read More

ctDNA & Liquid biopsy

Extensive R&D shows the excellence of the ctDNA cancer biomarker

Read More

Ultrasensitive cancer monitoring – redefined

SAGA Diagnostics has innovative technologies that are 100 times more sensitive in detecting and monitoring cancer compared to current methods. With our technology you can analyze an easily-collected “liquid biopsy” such as a blood sample, from the patient, and are not bound to traditional tissue biopsies.

The ultrasensitivity of our technology makes it possible to identify circulating tumor DNA (ctDNA) at an earlier stage, measure treatment response, and allow earlier better therapeutic decisions. Our products have the potential to improve the quality of life for thousands of cancer patients around the world.

Trusted supplier of services

Tissue and liquid biopsy testing services using SAGAsafe® and SAGAsign® are available to SAGA partners and customers. Both standard and flexible/customized solutions are available. All our testing is carried out in our own laboratory in Sweden. We support biopharmaceutical and academic R&D, clinical trials and the development of companion diagnostics.

Please inquire to find out how we can solve your testing needs and help drive your project forward.

Read More

Collaborating with leading researchers

The cancer liquid biopsy will transform the care of cancer patients. To remain on forefront of the liquid biopsy field, SAGA is collaborating with prominent researchers and clinicians addressing important issues that patients with lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, and leukemia, among others are facing.

Please reach out if you would like to work together to make precision medicine a reality for all patients.

Read More